Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol)[4][5] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.[6]
Clinical data | |
---|---|
Trade names | Incruse Ellipta |
Other names | GSK573719A |
License data |
|
Routes of administration | Inhalation (DPI) |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | ~89%[3] |
Metabolism | Liver (CYP2D6) |
Elimination half-life | 11 hours |
Excretion | Feces (58%) and urine (22%) |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.166.375 |
Chemical and physical data | |
Formula | C29H34BrNO2 |
Molar mass | 508.500 g·mol−1 |
3D model (JSmol) |
|
| |
|
It is on the World Health Organization's List of Essential Medicines.[7] In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[8][9]